← Back to Screener
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
Price$33.08
Favorite Metrics
Price vs S&P 500 (26W)-15.85%
Price vs S&P 500 (4W)4.56%
Market Capitalization$3.89B
All Metrics
Book Value / Share (Quarterly)$5.97
P/TBV (Annual)5.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-38.66%
Cash Flow / Share (Quarterly)$0.10
Price vs S&P 500 (YTD)-7.52%
Net Profit Margin (TTM)-905.74%
EPS (TTM)$-1.72
10-Day Avg Trading Volume0.79M
EPS Excl Extra (TTM)$-1.72
EPS (Annual)$-1.72
ROI (Annual)-29.82%
Cash / Share (Quarterly)$5.56
Revenue Growth QoQ (YoY)-99.75%
ROA (Last FY)-26.49%
Revenue Growth TTM (YoY)-50.61%
EBITD / Share (TTM)$-2.06
ROE (5Y Avg)-39.32%
Operating Margin (TTM)-1002.90%
Cash Flow / Share (Annual)$-1.29
P/B Ratio5.69x
P/B Ratio (Quarterly)5.82x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)151.02x
Net Interest Coverage (TTM)-6.44x
ROA (TTM)-25.56%
EPS Incl Extra (Annual)$-1.72
Current Ratio (Annual)7.88x
Quick Ratio (Quarterly)7.70x
3-Month Avg Trading Volume0.81M
52-Week Price Return106.98%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.97
P/S Ratio (Annual)172.80x
Asset Turnover (Annual)0.03x
52-Week High$42.00
EPS Excl Extra (Annual)$-1.72
CapEx CAGR (5Y)89.75%
26-Week Price Return-8.96%
Quick Ratio (Annual)7.70x
13-Week Price Return6.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.88x
Enterprise Value$3,398.467
Asset Turnover (TTM)0.03x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-905.74%
Cash / Share (Annual)$5.56
3-Month Return Std Dev52.47%
Net Income / Employee (TTM)$-2
ROE (Last FY)-29.82%
EPS Basic Excl Extra (Annual)$-1.72
EV / Free Cash Flow (TTM)303.25x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.72
ROI (TTM)-27.47%
P/S Ratio (TTM)172.80x
Revenue / Share (Annual)$0.19
Tangible BV / Share (Annual)$5.97
Price vs S&P 500 (52W)72.34%
Year-to-Date Return-3.59%
5-Day Price Return-1.80%
EPS Normalized (Annual)$-1.72
ROA (5Y Avg)-33.58%
Net Profit Margin (Annual)-905.74%
Month-to-Date Return5.65%
Cash Flow / Share (TTM)$-0.26
EBITD / Share (Annual)$-2.06
Operating Margin (Annual)-1002.90%
P/CF (TTM)360.68x
ROI (5Y Avg)-39.27%
EPS Basic Excl Extra (TTM)$-1.72
P/TBV (Quarterly)5.82x
P/B Ratio (Annual)5.82x
Pretax Margin (TTM)-905.74%
Book Value / Share (Annual)$5.97
Price vs S&P 500 (13W)3.87%
Beta0.14x
P/FCF (Annual)488.50x
Revenue / Share (TTM)$0.19
ROE (TTM)-27.47%
52-Week Low$15.82
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.33
4.33
4.32
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares | 172.80x | -50.61% | — | — | $33.08 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $899.91 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $224.87 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $205.74 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $112.62 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $196.15 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $148.70 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $38.87 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $94.12 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.37 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $58.80 |
About
NewAmsterdam Pharma is a biopharmaceutical company developing therapies for cardio-metabolic diseases, focusing on patients where current treatments are inadequate or poorly tolerated. The company's lead candidate, obicetrapib, is an oral CETP inhibitor designed to lower LDL cholesterol and address limitations of existing LDL-lowering treatments.